The promise of training the immune system to selectively destroy tumor cells — while sparing healthy tissue — has long been oncology's most elegant aspiration. Cancer vaccines are now moving from theoretical elegance toward clinical reality, but the path is neither linear nor uncomplicated. Understanding where the field actually stands matters enormously for patients, clinicians, and anyone tracking longevity medicine's most consequential frontier.
This comprehensive review catalogues the full spectrum of cancer vaccine approaches currently in use or under active investigation. Prophylactic vaccines — notably HPV and hepatitis B formulations — have already demonstrated population-level cancer prevention, reducing cervical and liver cancer incidence in vaccinated cohorts. On the therapeutic side, Sipuleucel-T (for metastatic castration-resistant prostate cancer) and T-VEC (an oncolytic herpes-based virus for advanced melanoma) represent the two FDA-approved therapeutic benchmarks, both offering survival extension rather than cure. The review systematically categorizes delivery platforms — mRNA, peptide-based, dendritic cell, and viral vector — and synthesizes clinical trial data across these modalities. A recurring theme is the tumor microenvironment: immunosuppressive signaling within solid tumors actively neutralizes vaccine-primed T-cell responses, and neoantigen heterogeneity between tumor subclones makes durable responses difficult to sustain.
From a broader research perspective, this review arrives at an inflection point. The same mRNA platform architecture that enabled rapid COVID-19 vaccine deployment is now being rapidly repurposed for personalized cancer neoantigens — Moderna and BioNTech both have Phase II/III trials underway for melanoma and other solid tumors. The combinatorial strategies pairing vaccines with PD-1/PD-L1 checkpoint inhibitors are particularly compelling, as they address the immune evasion problem the vaccines alone cannot solve. That said, this is a narrative review rather than a meta-analysis, limiting its ability to quantify comparative efficacy. The honest assessment: cancer vaccines are moving from incremental to potentially paradigm-shifting, but manufacturing scalability, equitable global access, and biomarker-driven patient selection remain rate-limiting constraints that no amount of scientific elegance resolves on its own.